Spotlight -

B + L Dry Eye Series|

Transforming Glaucoma Management|

Zeiss Clinical Cases

Viewing

|Videos|December 10, 2020

Violet light-filtering IOLs: visual and non-visual benefits

Author(s)David Hutton, Alex Delaney-Gesing

Daniel H. Chang, MD, speaks on the highlights of his presentation on "Violet Light-Filtering IOLs: Visual and Non-Visual Benefits," during the virtual AAO 2020 meeting.

Daniel H. Chang, MD, medical director, Empire Eye and Laser Center in Bakersfield, CA, speaks on the highlights of his presentation on "Violet Light-Filtering IOLs: Visual and Non-Visual Benefits," during the American Academy of Ophthalmology's virtual 2020 meeting.
See more AAO coverage here

Newsletter

Don’t miss out—get Modern Retina updates delivered straight to your inbox.

Related Content

Cynthia Toth, MD, of the Duke Department of Ophthalmology

Using OCT to predict neurodevelopmental risk in preterm infants: Cynthia Toth, MD

ByCytnthia Toth, MD,Lucia Gambuzza,Abigail Lewis, Content Intern

July 8th 2026

Charles Wykoff, MD, PhD | Modern Retina Video

Revakinagene taroretcel-lwey for MacTel: Charles Wykoff, MD, PhD, on a year of real-world experience

ByCharles C. Wykoff, MD, PhD,Lucia Gambuzza

July 2nd 2026

(Image credit: Modern Retina) The Wills Retina Report: Regillo and Garg on managing geographic atrophy—who, when, and how

The Wills Retina Report: Regillo and Garg on managing geographic atrophy—who, when, and how

ByCarl D. Regillo, MD, FACS, FASRS,Sunir J. Garg, MD, FACS, FASRS

June 26th 2026

(Image credit: Modern Retina/Ophthalmology Times)

Eichenbaum Acorns: From clinic to C-suite with Jay S. Duker, MD, and Ramiro Ribeiro, MD, PhD

ByDavid A. Eichenbaum, MD, FASRS,Jay S. Duker, MD ,Ramiro Ribeiro, MD, PhD

June 19th 2026

Mark Barakat, MD | Modern Retina CTS coverage

CTS 2026: OTX-TKI demonstrates superiority over aflibercept in wet AMD—what the SOL-1 data mean for retina practice

ByMark R. Barakat, MD,Lucia Gambuzza

June 15th 2026

Latest CME

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Basil Williams, MD; Maura Di Nicola, MD

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

John Kitchens, MD; Michael W. Stewart, MD

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Dilsher S. Dhoot, MD, FASRS

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Deep Parikh, MD

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

Uday Devgan, MD, FACS, FRCS

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO

(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

Damon Dierker, OD FAAO; Maria Pribis, OD

(CME Track) Embracing the Interventional Glaucoma Mindset: A Paradigm Shift in Contemporary Glaucoma Management

(CME Track) Embracing the Interventional Glaucoma Mindset: A Paradigm Shift in Contemporary Glaucoma Management

Mary Qiu, MD; Paul Singh, MD; Danica J. Marrelli, OD, FAAO

(CME Track) Reducing Treatment Burden in Retinal Disease Care With Extended-Duration Anti-VEGF Therapies

(CME Track) Reducing Treatment Burden in Retinal Disease Care With Extended-Duration Anti-VEGF Therapies

John Kitchens, MD

(CME Track) Cutting-Edge Care in Neovascular Retinal Disease: Expert Approaches to Selection and Interval Extension

(CME Track) Cutting-Edge Care in Neovascular Retinal Disease: Expert Approaches to Selection and Interval Extension

Geeta Lalwani, MD; Alla Goldberg, MD; Elite Bor-Shavit, MD

(COPE Track) Next-Generation Solutions for nAMD and DME: Bridging Evidence and Practice Gaps in Disease Management

(COPE Track) Next-Generation Solutions for nAMD and DME: Bridging Evidence and Practice Gaps in Disease Management

Murtaza K. Adam, MD, FASRS; Deepak Sambhara, MD, FASRS; Betty Zhang, OD

(COPE Track) Emerging Therapeutic Advancements in Dry Eye Disease Management

(COPE Track) Emerging Therapeutic Advancements in Dry Eye Disease Management

Rahul Tonk, MD; Jade Coats, OD, FAAO; Aaleya Koreishi, MD; Zeba Syed, MD

(COPE Track) Cutting-Edge Care in Neovascular Retinal Disease: Expert Approaches to Selection and Interval Extension

(COPE Track) Cutting-Edge Care in Neovascular Retinal Disease: Expert Approaches to Selection and Interval Extension

Geeta Lalwani, MD; Alla Goldberg, MD; Elite Bor-Shavit, MD

Trending on Eye Care Network - Ophthalmology Times

FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia

Alvotech files first known aflibercept 8 mg biosimilar with EMA

Duravyu misses noninferiority end point in phase 3 LUCIA wet AMD trial

FDA approves subcutaneous Enspryng for TED

Beyond slowing atrophy: Optogenetic therapy targets vision lost to GA